CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Bright Minds Biosciences Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Bright Minds Biosciences Inc
19 Vestry Street
Phone: (647) 865-8622p:647 865-8622 NEW YORK, NY  10013  United States Ticker: DRUGDRUG
Business Summary
Bright Minds Biosciences Inc. is a biotechnology company. The Company is focused on developing transformative treatments for neuropsychiatric disorders, epilepsy, and pain. It has a portfolio of next generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult to treat disorders such as treatment resistant epilepsy, treatment resistant depression, post-traumatic stress disorder (PTSD), and pain. Its pipeline includes BMB-101, BMB-202, and BMB-xxx. BMB-101 is for the treatment of Dravet syndrome and other neurological and neuro-psychiatric disorders. The Company has a portfolio of patented, selective serotonin (5-HT2C, 5-HT2A and 5-HT2C/A-receptor subtypes) agonists that were identified by using high-throughput screening methods in combination with advanced molecular modeling techniques to interrogate the interaction between the drug and its targeted receptors to increase downstream signaling while avoiding off-target effects.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/20239/30/2023YesYes---

Industries
SIC Code Description
2834 Pharmaceutical preparations
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
President, Chief Executive Officer, Director Ian B.Mcdonald 36 6/5/2020 5/31/2019
Chief Financial Officer RyanCheung 45 5/29/2020 5/29/2020
Chief Scientific Officer, Director JanPedersen 59 9/22/2022 4/27/2022
4 additional Officers and Directors records available in full report.

Business Names
Business Name
Bright Minds Bioscience Pty. Ltd.
Bright Minds Biosciences LLC
DRUG

General Information
Outstanding Shares: 4,463,837 (As of 12/31/2023)
Stock Exchange: CNQ


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Thursday, April 25, 2024